rinsada

What rinsada does

rinsada (0625, LLC) is a privately held, physician-founded medical device company headquartered in Wildwood, Pennsylvania, that develops and commercializes a single core product: the rinsada Irrigating Eyelid Retractor. The product is a sterile, single-use, FDA-cleared Class I device protected by US Patent No. 11,471,143, featuring a 5-port irrigation architecture that simultaneously retracts the eyelid and delivers high-pressure saline to the conjunctival fornix, palpebral conjunctiva, and bulbar conjunctiva — anatomical areas unreachable by standard eye rinses.

The device screws into a standard 10-cc Luer Lock syringe filled with sterile eye wash and is used in-office by optometrists and ophthalmologists for ocular surface conditions including allergic conjunctivitis, Demodex blepharitis, toxic conjunctivitis, Superior Limbic Keratoconjunctivitis (SLK), and post-injection lavage. Clinical evidence cited by the company includes >70% reduction in MMP-9 inflammatory markers and >40% of patients converting to MMP-9 negative after a Rinsada rinse. Since commercial launch in 2023, the device has been adopted by more than 250 US eyecare practices with 10,000+ cumulative devices used.

Rinsada generates revenue through direct hardware sales of the single-use device to eye care professionals via phone, email, and a professional login portal; pricing is not publicly disclosed and the procedure is positioned as potentially out-of-pocket. The company employs five people and is led by founder Dr. Srinivas Sai Kondapalli, a practicing ophthalmologist and retina specialist. Distribution has expanded from direct US sales to include a US Federal Fee Schedule Contract and, as of December 2025, an exclusive Canadian distribution agreement with Eye Drop Shop. The company is bootstrapped with no disclosed institutional funding, no parent company, and no public listing.

Name

rinsada

Legal name

0625, LLC

Website

https://rinsada.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Rinsada (0625, LLC) is a physician-founded medical device company that sells a sterile, single-use, FDA-cleared irrigating eyelid retractor to optometrists and ophthalmologists for in-office treatment of ocular surface conditions. The patented 5-port device reaches the conjunctival fornix unreachable by standard rinses.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)

Keywords

• Ophthalmic medical devices
• Ocular surface irrigation
• Eyelid retractor devices
• Dry eye treatment
• Eye care professional supplies

Headquarters

HQ city

Wildwood

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Personnel, Others

Revenue model

1. Single-Use Medical Device Sales: Rinsada generates revenue through the sale of sterile, single-use irrigating eyelid retractor devices to eye care professionals. The device is billed as an out-of-pocket procedure. Practices purchase directly from Rinsada via phone, email, or the professional login portal.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Rinsada designs, manufactures, and sells a sterile, single-use, FDA-cleared Class I irrigating eyelid retractor that attaches to a standard 10-cc Luer Lock syringe to deliver high-pressure irrigation to the conjunctival fornix, palpebral conjunctiva, and bulbar conjunctiva simultaneously. The patented 5-port device is sold directly to optometrists and ophthalmologists for in-office treatment of ocular surface conditions including dry eye, allergic conjunctivitis, Demodex blepharitis, toxic conjunctivitis, and SLK.

Product overview

rinsada offers a single core product — the rinsada™ Irrigating Eyelid Retractor — a sterile, single-use, FDA-cleared Class I medical device. The device is a mechanical irrigating eyelid retractor that simultaneously retracts the eyelid and delivers high-pressure irrigation to the entire ocular surface including the palpebral conjunctiva and fornix. It uses a standard 10-cc Luer Lock syringe filled with sterile eye wash solution and features a patented design with 5 micro-ports for distributing fluid in 3 directions. rinsada was invented by practicing ophthalmologist and retina specialist Dr. Srinivas Sai Kondapalli, and since its commercial launch in 2023, more than 10,000 devices have been used across over 250 eyecare practices in the United States. The company also maintains a patient-facing educational website at rinsemyeyes.com to support patient awareness and education.

Differentiator

Problem solved

Functional benefit

Products and services

• rinsada Irrigating Eyelid Retractor A sterile, single-use, FDA-cleared Class I irrigating eyelid retractor that delivers high-pressure saline irrigation to the conjunctival fornix, palpebral conjunctiva, and bulbar conjunctiva to remove ocular surface irritants, allergens, and inflammation. Features 5 irrigating micro-ports (2 on top crest, 2 on underside, 1 on forward tip) and screws onto a standard 10-cc Luer Lock syringe filled with eye wash. Indicated for optometrists and ophthalmologists treating allergic conjunctivitis, dry eye, Demodex blepharitis, toxic conjunctivitis, and Superior Limbic Keratoconjunctivitis (SLK).

Quantifiable outcome

• Over 70% reduction in MMP-9 inflammatory markers on ocular surface after Rinsada rinse
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Eye Drop ShopmajorChannel Partner/ Reseller/ Distributor · 15 December 2025Rinsada signed an exclusive distribution agreement with Eye Drop Shop, making them the sole distributor of Rinsada across Canada. Eye Drop Shop operates with Health Canada approval as an authorized distributor. Rinsada is officially registered with Health Canada, enabling nationwide availability through compliant, trusted channels. This partnership enables Canadian customers and clinicians to access Rinsada through a dedicated, experienced distribution partner known for excellence in eye-care product delivery.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• OCuSOFT: OCuSOFT sells lid hygiene and ocular surface products to optometrists and ophthalmologists. It targets the same ECP channel and blepharitis/ocular surface disease use cases, making it a relevant competitor for practice-level formulary decisions.
• BlephEx: BlephEx makes a handheld in-office device used by optometrists to clean the eyelid margin for blepharitis. It is directly comparable to Rinsada as a single-use/professional-use in-office ocular surface procedure device sold to the same ECP customer base.
• MiBo Medical Group: MiBo Medical sells in-office therapeutic devices for dry eye and ocular surface disease sold through optometry and ophthalmology channels. It competes for the same in-office procedure slot in ECP practices.
• Bruder Healthcare: Bruder sells moist heat compress and lid hygiene solutions for dry eye and blepharitis, sold through the same optometry/ophthalmology channels as Rinsada. It competes for shelf space and physician recommendation in ocular surface care.

Broad incumbents

• Bausch + Lomb: Bausch + Lomb's ophthalmic franchise (Lotemax, Vyzulta, MIEBO) addresses the same prescriber base and several of the same indications Rinsada targets, making it a relevant broad incumbent for competitive context.
• TearScience (Johnson & Johnson Vision): TearScience's LipiFlow is an established in-office dry eye procedure device. As a broad incumbent in physician-administered dry eye treatments, it overlaps with Rinsada's clinical positioning and ECP channel even though the mechanism differs.
• Alcon: Alcon is a global ophthalmic medical device and pharmaceutical leader with a deep surgical and dry eye portfolio (including Systane and iLux). It is a broad incumbent that shapes physician adoption patterns and competitive dynamics for ocular surface devices.

Emerging players

• Lacrivera: Lacrivera develops devices and therapeutics for ocular surface disease including dry eye. It is an emerging peer whose device-mechanism approach intersects with Rinsada's in-office procedural model.
• Sight Sciences: Sight Sciences develops interventional ophthalmic devices (TearCare for dry eye) sold to the same ECP customer base. It represents an emerging device-based competitor in the ocular surface treatment category.
• Tarsus Pharmaceuticals: Tarsus markets XDEMVY (lotilaner) for Demodex blepharitis, one of the indications Rinsada also targets. Although it is a pharmaceutical rather than a device, it competes for the same clinical decision in the same patient population.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rinsada

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about rinsada